(EBITDA) 34.53 17.06 17.47 102.38 Depreciation and amortization 23.56 19.76 3.80 19.22 Key financial ratio related with operating result (%) For the period ended Change 31 March 2020 31 March 2019 % YoY
the 2nd quarter financial statements as of August 31, 2019 which were reviewed by Deloitte Touche Tohmatsu Jaiyos Audit Company Limited. The operating performance is summarized as follows. Overview
% Core EPS after PERP Interest (THB) 0.85 0.67 1.31 (35)% 3.67 3.86 (5)% Core EBITDA/ton ($) 115 102 153 (25)% 119 132 (10)% Operating Cash Flow5 385 261 222 73% 1,172 855 37% Net Debt to Equity (times
. Analysis of Overall Operating Results for the Company and its subsidiary 1.1 Important circumstance during the year In April 2018, the Company acquired 800,000 ordinary shares of Aesthetic Zecret (AT-ZE
Thailand 1. Analysis of Overall Operating Results for the Company and its subsidiary 1.1 Important circumstance during the year In April 2018, the Company acquired 800,000 ordinary shares of Aesthetic Zecret
health and esthetics. 2. Overview of operating results for the year 2019. Thai’s economic has trend to growing lower continuously, Not only exporting business but Travelling business also have trend to
Thailand Ekachai Medical Care Public Company Limited (the “Company”) would like to clarify on the operating results for the yearly period at the end of 31st December 2018 as follows. Summary The Company
Microsoft Word - ผลการดำเนินงานQ2-2560_E.doc (Translated) Ref FSS 145/2016 August 22, 2017 Subject : The Explanation of operating results of the six-month period ending June 30th, 2017 To The
decrease in account payables following the lower raw material prices from last quarter. Accordingly, the total shareholders’ equity amounted to 3,521.17 million baht, increased by 104.30 million baht. These